Stallergenes obtains US FDA approval for pollen allergy drug Oralair
France-based Stallergenes has secured US Food and Drug Administration (FDA) approval for its immunotherapy tablet Oralair for treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Conjunctivitis | Food and Drug Administration (FDA) | Hay Fever | Pharmaceuticals